InvestorsHub Logo
Followers 6
Posts 6914
Boards Moderated 0
Alias Born 07/27/2003

Re: None

Monday, 05/08/2006 9:21:20 AM

Monday, May 08, 2006 9:21:20 AM

Post# of 64738
NEWS, NEWS, NEWS, NEWS!!!!!!!

CytoGenix and USDA to Collaborate in Developing a synDNA(TM) Vaccine Against Costly Livestock Disease
CytoGenix, Inc. (OTCBB:CYGX) announced that it has entered into a formal Cooperative Research and Development Agreement (CRADA) with the USDA Agricultural Research Service.

CytoGenix scientists will work with a team of USDA scientists led by Dr. Steven Olsen to develop synDNA(TM) vaccines against existing and emerging strains of the bacteria that causes brucellosis, a costly disease for ranchers and game managers. Brucellosis causes miscarriages in domestic sheep, goats, cattle, pigs, and in wildlife such as deer, elk and bison. State and Federal governments have spent $11 billion over the last 45 years in an attempt to eradicate this disease.

Dr. Olsen, Director of Vaccine Research for the Agricultural Research Service, USDA commented, "There remain reservoirs of brucella in wildlife within Yellowstone Park, and the potential for brucellosis infection is a serious threat to cattle ranchers in the region. For this reason, ARS has been conducting research to develop DNA vaccines for brucella infections for several years."

Dr. Malcolm Skolnick, CytoGenix Chief Executive Officer, commented, "We are pleased to be working with Dr. Olsen and his team of scientists at USDA. ARS is a leader within the Federal government in the transferal and marketing of new technologies developed from its research laboratories. This CRADA is another example of our commitment to exploring the utility of synDNA(TM) technology in cooperation with governmental agencies."




"If the facts don't fit the theory, change the facts."

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.